Last reviewed · How we verify
Regulatory T-cell enriched infusion
At a glance
| Generic name | Regulatory T-cell enriched infusion |
|---|---|
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease (PHASE1)
- Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies (PHASE2, PHASE3)
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (PHASE1)
- Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (PHASE1)
- IS-free Treg HaploHCT (PHASE1)
- Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib (PHASE2)
- Multiple Donor Treg DLI for Severe Refractory Chronic GVHD (PHASE1, PHASE2)
- Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: